Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes.

MLA

Tomlinson, Brian, et al. “Evaluation of the Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of Empagliflozin for the Treatment of Type 2 Diabetes.” Expert Opinion on Drug Metabolism & Toxicology, vol. 13, no. 2, Feb. 2017, pp. 211–23. EBSCOhost, https://doi.org/10.1080/17425255.2017.1258401.

APA

Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2017). Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology, 13(2), 211–223. https://doi.org/10.1080/17425255.2017.1258401

Chicago

Tomlinson, Brian, Miao Hu, Yuzhen Zhang, Paul Chan, and Zhong-Min Liu. 2017. “Evaluation of the Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of Empagliflozin for the Treatment of Type 2 Diabetes.” Expert Opinion on Drug Metabolism & Toxicology 13 (2): 211–23. doi:10.1080/17425255.2017.1258401.